Exhibit 10.17(a)
Confidentiality Requested by
Emisphere Technologies, Inc.
SEC File No. 1-10615
PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. SUCH PORTIONS ARE DESIGNATED "[***]."
This Agreement is made as of the 7th day of April, 1998
BY AND BETWEEN
Xxx Xxxxx & Company
An Indiana Corporation with offices at Lilly Xxxxxxxxx Xxxxxx, Xxxxxxxxxxxx,
Xxxxxxx 00000
Emisphere Technologies, Inc.
A Delaware Corporation with offices at 00 Xxxxxxx Xxxxx, Xxxxxxxxx, Xxx Xxxx
00000
LICENSE AGREEMENT
Confidentiality Requested by
Emisphere Technologies, Inc.
SEC File No. 1-10615
TABLE OF CONTENTS
Section Page
1 DEFINITIONS.......................................................2
2 GRANT OF RIGHTS..................................................13
3 IMPROVEMENTS.....................................................14
4 MANUFACTURING ...................................................15
5 RESEARCH AND DEVELOPMENT.........................................16
6 SUPPLY OF PRODUCT(S).............................................17
7 EXPLOITATION OF LICENSED TECHNOLOGY..............................17
8 FINANCIAL PROVISIONS.............................................18
9 RIGHT OF AUDIT AND INSPECTION....................................20
10 PATENTS..........................................................21
11 CONFIDENTIAL INFORMATION.........................................25
12 TERM OF AGREEMENT................................................27
13 WARRANTIES/INDEMNITIES...........................................30
14 REGULATORY APPROVALS.............................................35
15 INSURANCE........................................................36
16 IMPOSSIBILITY OF PERFORMANCE - FORCE MAJEURE.....................36
17 SETTLEMENT OF DISPUTES; PROPER LAW...............................36
18 ASSIGNMENT.......................................................37
19 NOTICES..........................................................37
20 MISCELLANEOUS CLAUSES............................................38
Confidentiality Requested by
Emisphere Technologies, Inc.
SEC File No. 1-10615
WHEREAS
-------
A. Emisphere is beneficially entitled to the use of various patents,
including the Emisphere Patents which have been granted or are pending
under various international conventions in relation to the Emisphere
Technology.
B. Emisphere is knowledgeable in the discovery and use of compounds which can
interact with therapeutic agents in a manner to improve the transport of
such therapeutic agents through biological membranes.
X. Xxxxx is knowledgeable in the research, development, manufacture and
marketing of pharmaceutical formulations. Lilly owns and possesses
patented therapeutic agents and other technologies.
D. Emisphere and Lilly have previously entered into a Research Collaboration
and Option Agreement regarding the Emisphere Technology.
X. Xxxxx desires to enter into this Agreement with Emisphere so as to (a)
permit Lilly to utilize the Emisphere Patents and the Emisphere Know-How
in the research, development, manufacture, distribution and sale of the
Products and other products in the Field and (b) to permit Lilly to
utilize the Emisphere Program Technology in combination with the Lilly
Program Technology in connection with (i) research and development work
conducted by the Parties and (ii) Lilly's manufacture and supply of
Products and other related components.
1
Confidentiality Requested by
Emisphere Technologies, Inc.
SEC File No. 1-10615
NOW IT IS HEREBY AGREED AS FOLLOWS:
1. DEFINITIONS
1.1 In this present Agreement, including the Recitals and Appendix, the
following definitions shall prevail unless the context otherwise requires:
"Acquired" means a transfer of intellectual property or information from
an Independent Third Party to Emisphere or Lilly, as the case
may be, to the extent to which there are no obligations or
restrictions as to confidentiality in respect of that
information which prohibit disclosure or use by Lilly or
Emisphere, as appropriate;
"Activation
Letter" is the notification document (a copy of which is attached as
Schedule II hereto) received by Emisphere from a senior Lilly
officer or representative with appropriate legal
responsibility to render this Agreement binding on Lilly with
respect to a single Compound and a single Route of
Administration, both identified therein;
"Affiliate" means any corporation or business entity which Lilly or
Emisphere, directly or indirectly, owns or controls, is under
common ownership with, or which owns one of the Parties to
this Agreement. Ownership or control shall exist when an
entity owns more than 50% of the capital or business assets
of another entity; has the power to exercise more than 50% of
the voting rights or to appoint more than 50% or more of the
Board of Directors of another entity; or has the right to
control the affairs of another entity. It being understood
that the direct or indirect ownership of a lesser percentage
of such shares shall not necessarily preclude the existence
of control;
"Agreement" means this license agreement (which expression shall be
deemed to include the Recitals, Schedules and Appendix
hereto, and any other document(s) incorporated herein by
reference);
"Carriers" means various agents that are used to facilitate transport
through membranes via a number of different Routes of
Administration to deliver the
2
Confidentiality Requested by
Emisphere Technologies, Inc.
SEC File No. 1-10615
Compounds utilizing the Emisphere Technology and/or the
Emisphere Program Technology. These agents can include, but
are not limited to proteins, peptides and other chemicals;
"Compound(s)" means the therapeutic agent specified by Lilly in the
Activation Letter (in this Agreement, the parathyroid hormone
molecule and all active fragments, analogs, PTH-like peptides
with primary function similar to the PTH molecule (not to
include secretagogues) and mimetics);
"Cost" means, depending upon the context, one of the following:
In the case of research and development, Cost will be
calculated in accordance with Emisphere's internal accounting
system, will exclude any element of corporate overhead and
will be in accordance with Generally Accepted Accounting
Principles ("GAAP").
In the case of materials purchased from an Independent Third
Party, Cost will comprise the amount actually paid, including
import duties, transport and handling costs and other
directly attributable costs, in accordance with GAAP;
"Effective Date" means the date Emisphere receives the Option Exercise
Payment;
"Emisphere" means Emisphere Technologies, Inc., its Affiliates,
successors and permitted assignees;
"Emisphere
Know-How" means all trade secrets, confidential scientific, technical
and medical information and expertise from time to time
developed, produced, created or Acquired by or on behalf of
Emisphere, on or before the Effective Date (i.e., excluding
Emisphere Program Know-How, Joint Know-How and Improvements),
including, but not limited to, unpatented inventions,
discoveries, theories, plans, ideas or designs (whether or
not reduced to practice) relating to the research and
development, registration for marketing, use or sale of the
Carriers or the Product(s), needed relevant data on the
Carriers, preclinical toxicity and manufacturing
3
Confidentiality Requested by
Emisphere Technologies, Inc.
SEC File No. 1-10615
data for the Carriers and prototype Product(s), and
toxicological, pharmacological, analytical and clinical data,
bioavailability studies, formulations, control assays and
specifications, methods of preparation and stability data
with respect to the Carriers and prototype Product(s);
"Emisphere
Patents" means all and any patents, utility models and any
applications therefor in the Territory (other than the
Emisphere Program Patents or Joint Patents) that are or
subsequently may be owned or Acquired by, or assigned or
licensed to, Emisphere (including any and all divisions,
continuations, continuations-in- part, extensions, additions,
registrations, confirmations, reexaminations, Supplementary
Protection Certificates, renewals or reissues thereto or
thereof) and that would be infringed by the development,
manufacture, use, disposal, sale, offer of disposal or sale,
or importation of the Product(s) in the Territory and/or
relate to the Field; the Emisphere Patents as of the date
hereof are listed on Schedule I hereto;
"Emisphere Program
Know-How" means all trade secrets, confidential scientific, technical
and medical information and expertise developed, produced,
created or Acquired by or on behalf of Emisphere pursuant to
the Research and Development Program (other than Emisphere
Know-How and Joint Know-How), including, but not limited to,
unpatented inventions, discoveries, theories, plans, ideas or
designs (whether or not reduced to practice), and relating to
the research and development, registration for marketing, use
or sale of the Carriers or the Product(s), needed relevant
data on the Carriers, preclinical toxicity and manufacturing
data for the Carriers and prototype Product(s), and
toxicological, pharmacological, analytical and clinical data,
bioavailability studies, formulations, control assays and
specifications, methods of preparation and stability data
with respect to the Carriers and prototype Product(s);
Emisphere Program Know-How shall not include any trade
secrets, information and expertise developed, produced,
created or Acquired by or on behalf of Emisphere pursuant to
the Research and Development Program relating to the
Compounds
4
Confidentiality Requested by
Emisphere Technologies, Inc.
SEC File No. 1-10615
or their therapeutic uses or properties as such trade
secrets, information and expertise shall be Lilly Program
Know-How;
"Emisphere Program
Patents" means all and any patents, utility models and applications
therefor in the Territory (including any and all divisions,
continuations, continuations-in-part, extensions, additions,
registrations, confirmations, reexaminations, Supplementary
Protection Certificates, renewals or reissues thereto or
thereof) on or for any inventions or discoveries that (i)
have been or subsequently may be conceived or made by
employees or agents of Emisphere pursuant to the Research and
Development Program (regardless of when or by whom such
inventions and/or discoveries are reduced to practice) or
(ii) relate to the Carriers or the use thereof for delivery
of Compounds (regardless of when or by whom such inventions
and/or discoveries are reduced to practice or by whom they
are conceived);
"Emisphere Program
Technology" means the Emisphere Program Patents, the Emisphere Program
Know-How and/or Emisphere's share of the Joint Patents and
the Joint Know-How;
"Emisphere
Technology" means the Emisphere Patents and/or the Emisphere Know- How;
"Ex Works" shall have the meaning as such term is defined in the ICC
Incoterms, 1990, International Rules for the Interpretation
of Trade Terms, ICC Publication No. 460;
"FDA" means the United States Food and Drug Administration or any
successors or agency the approval of which is necessary to
market a product in the United States of America or any other
relevant regulatory authority the approval of which is
necessary to market a product in any other country of the
Territory;
"Field" means the research, development and optimization of the
Compound specified in the Activation Letter
5
Confidentiality Requested by
Emisphere Technologies, Inc.
SEC File No. 1-10615
utilizing one or more Carriers for all medical ailments or
indications for the Route of Administration (in this
Agreement, the oral route) specified in the Activation Letter
as well as the manufacture, use, promotion, distribution,
marketing and sale of the Product(s);
[* * *] means, in the case of supply of Carrier(s), [* * *].
"Improvements" means inventions, discoveries, developments and indications
conceived by Emisphere, and relating to the Emisphere
Technology, that can usefully be applied to the Field, the
Lilly Program Technology and/or the Emisphere Program
Technology, and which were first reduced to practice during
the term of this Agreement by Emisphere whether or not such
modification adds any benefit to the Field, the Lilly Program
Technology, the Emisphere Program Technology, or the Joint
Technology;
"INDA" means any Investigational New Drug Application in relation to
a Product(s) filed by Lilly or its approved designee with the
FDA or a similar application filed in another jurisdiction;
"Independent
Third Party" means any person other than Lilly, Emisphere or any of
their Affiliates;
"Joint Know-How" means all trade secrets, confidential scientific,
technical and medical information and expertise, technical
data and marketing information, studies and data developed,
produced, created or Acquired jointly by the Parties during
the term of this Agreement pursuant to the Research and
Development Program, including, but not limited to,
unpatented inventions, discoveries, theories, plans, ideas or
designs; Joint Know-How shall not include any trade secrets,
confidential scientific, technical and medical information
and expertise, technical data and marketing information,
studies and data developed, produced, created or Acquired
jointly by the Parties pursuant to the Research and
Development Program to the extent any of such items relate to
either (i) Carriers or the use thereof for delivery of
Compounds or (ii) the Compounds or their therapeutic uses or
properties, since such items relating to Carriers and
6
Confidentiality Requested by
Emisphere Technologies, Inc.
SEC File No. 1-10615
such use thereof shall be considered Emisphere Program
Know-How and such items relating to Compounds and the
therapeutic uses or properties thereof shall be considered
Lilly Program Know-How;
"Joint Patents" means all and any patents, utility models and any
applications therefor in the Territory (including any and all
divisions, continuations, continuations-in-part, extensions,
additions, registrations, confirmations, reexaminations,
Supplementary Protection Certificates, renewals or reissues
thereto or thereof) on or for any inventions or discoveries
that are jointly conceived by the Parties during the term of
this Agreement pursuant to the Research and Development
Program (regardless of when or by whom such inventions and/or
discoveries are reduced to practice) that do not relate to
(i) the Carriers or the use thereof for delivery of Compounds
nor to (ii) the Compounds or their therapeutic uses or
properties (i.e., other than Emisphere Patents, Emisphere
Program Patents, Lilly Patents and Lilly Program Patents);
"Launch" means the commercial sale (including promotion) of a Product;
the date thereof shall be determined on a country-by-country
basis.
"Lilly" means Xxx Xxxxx & Company, its Affiliates, successors and
permitted assignees;
"Lilly Know-How" means all trade secrets, confidential scientific,
technical and medical information and expertise, technical
data and marketing information, studies and data from time to
time developed, produced, created or Acquired by or on behalf
of Lilly, whether before the Effective Date or during the
term of this Agreement (other than the Lilly Program Know-How
or Joint Know-How), including, but not limited to, unpatented
inventions, discoveries, theories, plans, ideas or designs
(whether or not reduced to practice), relating to the
research and development, manufacture, registration for
marketing, use or sale of the Product(s), and toxicological,
pharmacological, analytical and clinical data,
bioavailability studies, product forms and formulations,
control assays and
7
Confidentiality Requested by
Emisphere Technologies, Inc.
SEC File No. 1-10615
specifications, methods of preparation and stability data
with respect to the Product(s);
"Lilly Patents" means all and any patents, utility models and any
applications therefor in the Territory (other than the Lilly
Program Patents or Joint Patents) that are or subsequently
may be owned or acquired by or assigned or licensed to Lilly
(including any and all divisions, continuations,
continuations-in-part, extensions, additions, registrations,
confirmations, reexaminations, Supplementary Protection
Certificates, renewals or reissues thereto or thereof) and
that would be infringed by the development, manufacture, use,
disposal, sale, offer of disposal or sale, or importation of
the Product(s) in the Territory and/or relate to the Field;
"Lilly Program
Know-How" means all trade secrets, confidential scientific, technical
and medical information and expertise, technical data and
marketing information, studies and data developed, produced,
created or Acquired by or on behalf of Lilly, pursuant to the
Research and Development Program (other than the Lilly
Know-How and Joint Know-How), including, but not limited to,
unpatented inventions, discoveries, theories, plans, ideas or
designs (whether or not reduced to practice), relating to the
research and development, manufacture, registration for
marketing, use or sale of the Product(s), needed relevant
data generated by Lilly (including preclinical toxicity data)
on the Product(s) and toxicological, pharmacological,
analytical and clinical data, bioavailability studies,
product forms and formulations, control assays and
specifications, methods of preparation and stability data
with respect to the Product(s); Lilly Program Know-How shall
not include any trade secrets, information and expertise
developed, produced, created or Acquired by or on behalf of
Lilly pursuant to the Research and Development Program
relating to the Carriers or the use thereof for delivery of
Compounds, as such trade secrets, information and expertise
shall be Emisphere Program Know-How;
"Lilly Program
8
Confidentiality Requested by
Emisphere Technologies, Inc.
SEC File No. 1-10615
Patents" means all and any patents, utility models and applications
therefor in the Territory (including any and all divisions,
continuations, continuations-in-part, extensions, additions,
registrations, confirmations, reexaminations, Supplementary
Protection Certificates, renewals or reissues thereto or
thereof) on or for any inventions or discoveries that (i)
have been or subsequently may be conceived or made by
employees or agents of Lilly pursuant to the Research and
Development Program (regardless of when or by whom such
inventions and/or discoveries are reduced to practice) or
(ii) relate to the Compounds or their therapeutic uses or
properties (regardless of when or by whom such inventions
and/or discoveries are reduced to practice or by whom they
are conceived);
"Lilly Program
Technology" means the Lilly Program Patents, the Lilly Program Know- How
and/or Lilly's share of the Joint Patents and the Joint
Know-How;
"Lilly Technology" means the Lilly Patents and/or the Lilly
Know-How;
[* * *] means a manual, a table of contents of which is attached
hereto as Appendix I, containing certain specifications,
procedures, methods and personnel contacts relating to [* *
*] that will be compiled and agreed upon between the Parties
prior to the commencement of manufacture of the Carrier(s) by
Emisphere. Sections of the [* * *] may be modified from time
to time through the issuance of a revised section
incorporating the modification and stating the effective date
of the modification. Each such revised section shall be
signed on behalf of the Parties by a duly authorized
representative. The duly authorized representative shall be
of a management level no lower than the management level of
the duly authorized representative who signed that section of
the original [* * *].
"Milestone" means milestones as specified in Appendix 1 to the Option
Agreement, as modified by the Activation Letter attached
hereto as Schedule II;
"NDA" means any New Drug Application in relation to a Product(s)
filed by Lilly or its approved designee with
9
Confidentiality Requested by
Emisphere Technologies, Inc.
SEC File No. 1-10615
the FDA or a similar application filed in another
jurisdiction;
"Net Sales" means with respect to the Product(s) the gross amount
invoiced by Lilly, its Affiliates and/or any sub- licensee of
Lilly or its Affiliates to unrelated third parties for the
Product(s) less the following seven items: (a) trade quantity
and cash discounts actually allowed; (b) commission,
discounts, refunds, rebates, charge backs, retroactive price
adjustments, and any other allowances which effectively
reduce the net selling price; (c) actual product returns and
allowances; (d) that portion of the sales value associated
with non pharmaceutical drug delivery devices (not to include
Emisphere's Carriers); (e) any tax imposed on the production,
sale, delivery or use of the Product(s); (f) allowance for
distribution (transportation) expenses (limit of [* * *] of
gross sales); (g) any other similar, reasonable and customary
deductions which are properly recorded as a reduction of
sales under GAAP, consistently applied.
In the event that the Product is sold as part of a
combination product, the Net Sales of Product, for purposes
of determining royalty payments, shall be determined by
multiplying the Net Sales of the combination product by the
fraction, A/(A+B) where A is the average sales price of the
Product when sold separately in finished form and B is the
average sales prices of the other product(s) sold separately
in finished form; in the event that such average sales price
cannot be determined for both Product and the other
products(s) used in the combination product, Net Sales for
the purposes of determining royalty payments shall be
calculated by multiplying the Net Sales of the combination
product by the fraction C/(C+D) where C is Lilly's cost of
goods for the Product and D is Lilly's cost of goods of the
other products(s) used in the combination product, determined
in accordance with the method of accounting normally employed
by Lilly in computing cost of goods.
10
Confidentiality Requested by
Emisphere Technologies, Inc.
SEC File No. 1-10615
"Option" means the option to enter into a license agreement in the
form of this Agreement, as provided for in the Option
Agreement;
"Option Agreement" means that certain Research Collaboration and
Option Agreement, dated as of February 26, 1997, between
Emisphere and Lilly, incorporated herein by reference;
"Option Exercise
Payment" means the Milestone payment specified in Appendix 1 to the
Option Agreement and the payment of which is required upon
execution of this Agreement;
"Parties" means Lilly and Emisphere;
"Person" means an individual, partnership, corporation, limited
liability company, business trust, joint stock company,
trust, unincorporated association, joint venture, or other
entity of whatever nature;
[* * *] means a system of (1) developing standard costs at
levels which would be incurred if [* * *] or (2) analyzing
and reporting variances caused by [* * *] of resources;
practical capacity means the volume, usually expressed in
hours or minutes, which a plant, department or work center
can achieve in an operating period under normal but efficient
operating conditions and assuming sufficient volume is
available; it measures the amount one is prepared to make or
sell and includes allowances for unavoidable down time;
"Product(s)" means, depending on the context, one or more formulations of
the Compound(s) with one or more of the Carriers for a
specific Route of Administration that complies with the
Specifications;
"Research and
Development
Program" means the joint program of research and development work,
with respect to the Field and the Product, being conducted or
to be conducted by, inter alia, Lilly and Emisphere for and
on behalf of Lilly, for which both Parties are responsible,
and which has been devised by and approved by the Steering
Committee; the Research and Development Program shall not
include
11
Confidentiality Requested by
Emisphere Technologies, Inc.
SEC File No. 1-10615
work for which Lilly alone is responsible, such as clinical
trials of Product(s);
"Route
of Administration" means administration of the Compound(s) by
the oral route;
"Specifications" means the specifications for each of the Carriers or
Product(s) as approved by the FDA, as well as such other
specifications which may be agreed upon by the Parties in
writing or by the Steering Committee;
"Steering
Committee" means the management committee appointed by Emisphere and
Lilly to oversee the Research and Development Programs
related to the Product(s);
"Territory" means all the countries of the world; and
"United States
Dollars"
and "US$" means the lawful currency for the time being of the
United States of America.
1.2 In this Agreement:
1.2.1 The singular includes the plural and vice versa.
1.2.2 Any reference to a Clause shall, unless otherwise specifically
provided, be to a Clause of this Agreement.
1.2.3 The headings of this Agreement are for ease of reference only and
shall not affect its construction or interpretation.
2. GRANT OF RIGHTS
In consideration of the receipt of the Activation Letter specifying the Compound
and the Route of Administration to be licensed and simultaneous receipt of the
first Milestone payment by Emisphere (both from Lilly), the receipt and adequacy
of which is acknowledged by Emisphere to Lilly by Emisphere's acceptance of the
Activation Letter and Milestone payment, Emisphere grants to Lilly for the term
of this Agreement:
2.1 an exclusive license to use (a) the Emisphere Patents, the Emisphere
Program Patents and Emisphere's share of the Joint Patents for the Field,
and (b) the Emisphere Know-How, the Emisphere Program Know-How and
Emisphere's share of the Joint Know-How for the Field. All proprietary
rights and rights of ownership with respect to the Emisphere Technology
and Emisphere Program
12
Confidentiality Requested by
Emisphere Technologies, Inc.
SEC File No. 1-10615
Technology shall at all times remain solely with Emisphere unless
otherwise specified in this Agreement. Lilly shall not have any rights to
use the Emisphere Technology or Emisphere Program Technology other than
insofar as they relate directly to the Field and are expressly granted
herein.
2.2 Subject to Clause 6.3, Lilly shall have the right to sublicense the rights
granted to it by Emisphere pursuant to this Agreement. Insofar as the
obligations owed by Lilly to Emisphere are concerned, Lilly shall remain
responsible for all acts and omissions of any sub-licensee as if they were
by Lilly. Lilly shall forthwith notify Emisphere of any sub-license
granted by Lilly. In all cases, (i) royalties shall be paid at the rate
provided for herein (i.e., in accordance with the relevant Option
Agreement Appendix); and (ii) the applicable royalty rate shall be
determined with reference to market share or net sales figures (as the
case may be) determined by cumulating all sales of the Product by Lilly
and all of its sub-licensees. It shall be Lilly's responsibility in all
cases to determine the cumulated net sales or market share data and assure
that Emisphere is paid (whether by Lilly or the sub-licensee) the
royalties at the increased rate provided for upon reaching the yearly
targets, all as set forth in the relevant Appendix of the Option
Agreement. If Emisphere does not receive payment from a sublicensee
within [* * *] days of the end of each quarter, Emisphere shall
immediately notify Lilly's royalty administration personnel (contact name
shall be provided once Product is Launched) that payment has not been
remitted. If unforeseen circumstances result in a sublicensee not
reporting to Lilly, the amount of their Net Sales such that Lilly cannot
determine the cumulative Net Sales or market share data, Lilly shall pay
Emisphere its royalty due on Lilly Net Sales only and within [* * *] days
of the end of such calendar quarter, ensure that Emisphere will receive
the appropriate amount of royalties from either the sublicensee or Lilly.
Notwithstanding the previous sentence however, Net Sales by sublicensees
shall not be counted twice in the calculation of royalty payments due to
Emisphere. In the event of a termination of this Agreement due to a
breach by Lilly, Emisphere shall have the right but not the obligation to
assume any such sub-license under the same terms.
In consideration of the obligations assumed hereunder, Lilly grants to
Emisphere, solely for the purposes of carrying out the latter's obligations
hereunder:
2.3 a non-exclusive license to use the Lilly Technology and the Lilly Program
Technology. All proprietary rights and rights of ownership with respect
to the Lilly Technology and the Lilly Program Technology shall at all
times remain solely with Lilly, unless otherwise specified in this
Agreement. Emisphere shall not have any rights to use the Lilly
Technology or the Lilly Program Technology other than insofar as expressly
granted herein.
13
Confidentiality Requested by
Emisphere Technologies, Inc.
SEC File No. 1-10615
2.4 Emisphere shall have no right to sublicense the rights granted to it by
Lilly pursuant to this Agreement except as expressly authorized by Lilly.
Insofar as the obligations owed by Emisphere to Lilly are concerned,
Emisphere shall remain responsible for all acts and omissions of any
approved sub-licensee as if they were by Emisphere.
3. IMPROVEMENTS
3.1 If Emisphere shall develop or have developed by an Independent Third Party
any Improvements during the term of this Agreement (other than pursuant to
the Research and Development Program which constitute Emisphere Program
Technology), Emisphere shall, to the extent that it is not prohibited by
any undertaking given to any Independent Third Party (provided that
Emisphere shall use its commercially reasonable efforts to exclude or
minimize the extent of any such limitations or restrictions which prevent
or limit disclosure to or use by Lilly), communicate to Lilly such
Improvements and shall provide to Lilly such rights, licenses, information
and explanations as Lilly may reasonably require to be able effectively to
utilize the Improvements for the life of this Agreement. Such disclosed
Improvements shall automatically on disclosure to Lilly become part of the
Emisphere Know-How or Emisphere Patents, as the case may be, and shall be
subject to the provisions of this Agreement.
4. MANUFACTURING
4.1 Lilly will manufacture final Product(s). Emisphere will manufacture at
least [* * *] of the Carrier needed for Product sales. Lilly will pay
Emisphere the latter's [* * *] on all Carrier used for sales of Products
less than or equal to the sales schedule set forth in the relevant
Appendix to the Option Agreement. Above the Product sales level specified
in the relevant Appendix of the Option Agreement, Lilly will pay
Emisphere's direct manufacturing costs (calculated according to the [* *
*]. Lilly will be permitted to manufacture up to [* * *]% of the Carrier
needed to manufacture the Products. If Lilly can find a Carrier source
that can offer a supply price that is at least [* * *]% lower than
Emisphere's supply price (including Lilly, with supply price in such case
being [* * *] all determined in accordance with GAAP principles), Lilly
may use such supplier for up to [* * *]% of the Carrier needed to
manufacture the Product. So long as Lilly uses it as a supplier of
Carrier, Emisphere will hold at minimum [* * *] of Carrier inventory per
year to be determined at the appropriate time. Emisphere's manufacturing
operations will meet any required regulatory agency's specifications for
registration, as set forth in the [* * *].
14
Confidentiality Requested by
Emisphere Technologies, Inc.
SEC File No. 1-10615
4.2 Lilly shall be permitted to produce Carrier for its use in clinical
trials, but only until Emisphere is able to supply the Carrier pursuant to
the terms of Section 4.1.
4.3 Lilly reserves the right to audit the facility of Emisphere as specified
in the [* * *], including its processes, records, and other facets of the
operation as may be necessary to assure that all applicable FDA or similar
government regulations have been met. Emisphere shall permit duly
authorized representatives of Lilly to audit all research, development and
manufacturing areas and operations as they apply to Emisphere projects or
Carriers for Lilly at reasonable times with a prior appointment. The
right to audit will also apply to Carrier used in trials to support
product registration. These audits will be conducted to assure compliance
with all pertinent acts, regulations, and guidelines promulgated by the
FDA and other regulatory authorities. Such audits will be permitted
during normal business hours and will be performed with a minimum of
disruption. Lilly shall furnish to Emisphere copies of all reports
prepared as a result of these audits. Lilly agrees to notify Emisphere
within [* * *] of any concerns that it may have regarding Carrier(s).
Lilly will also have the right to audit Emisphere's financial
manufacturing records in accordance with Clause 9.2.
5. RESEARCH AND DEVELOPMENT
5.1 Subject to any and all specific provisions included in the Option
Agreement or relevant Appendix, and to the extent Emisphere does not have
the requisite capability or resources or Lilly elects to do so itself,
Lilly agrees to use Emisphere, on terms to be negotiated in good faith, to
conduct the Research and Development Program. Upon agreement by the
Parties as to the appropriate amount of compensation to Emisphere
therefor, Emisphere shall conduct its portion of such Research and
Development Program.
5.2 Subject to any and all specific provisions included in the Option
Agreement or relevant Appendix, the research and development work
conducted jointly by the Parties shall be in accordance with the Research
and Development Program devised by the Steering Committee. Both Parties
shall use reasonably diligent efforts, consistent with their efforts on
other projects of similar commercial importance and state of development,
to conduct their respective portions of the Research and Development
Program.
5.3 Subject to any and all specific provisions included in the Option
Agreement or relevant Appendix, the Research and Development Program shall
be directed by the Steering Committee. In conducting the Research and
Development Program, each Party shall co-operate fully with the Steering
Committee. Each Party shall maintain the facilities used by it for the
performance of the Research and Development Program in compliance with the
applicable
15
Confidentiality Requested by
Emisphere Technologies, Inc.
SEC File No. 1-10615
requirements of the FDA and other regulatory authorities, including
then-current Good Manufacturing Practices and then-current Good Laboratory
Practices standards.
5.4 Subject to any and all specific provisions included in the Option
Agreement or relevant Appendix, Emisphere shall provide Lilly on a
quarterly basis during the term of the Research and Development Program a
report, detailing how Emisphere allocated funds provided by Lilly for such
Program, if Lilly provided any such funds. Such report shall provide
Lilly with the names of the Emisphere employees utilized on the Program
and the amount of each employee's time devoted to the Program. Emisphere
shall, further, maintain records in reasonable detail and in accordance
with GAAP of all monies paid by Emisphere for research under the Program
and shall provide Lilly, within [* * *] of the end of each quarterly
period, with a report stating the dollar amount of funds supplied by Lilly
that were expended on research activities during the three month period
for which the report is made, using Emisphere's standard project
accounting procedures, and such supporting details as are reasonably
required by Lilly. Lilly shall be entitled to any tax credits due on
account of research and development expenses, to the extent permitted by
law, for the funds paid by Lilly to Emisphere hereunder. Also, Lilly may
have the costs of the Research and Development Program audited in
accordance with Clause 9.2.
6. SUPPLY OF PRODUCT(S)
6.1 Except as otherwise herein provided in this Agreement, Lilly shall produce
and supply the final commercial Product(s). Any chemical (not including
the Carriers) or formulation components required to make use of the
Emisphere Technology shall be procured by Lilly at its own Cost. Lilly
shall ensure that supplies of the Product(s) are produced as diligently as
any of its products of similar commercial importance.
6.2 Lilly shall deliver the Product(s) in appropriate packaging as specified
in the [* * *] so as to permit safe storage and transport.
6.3 In the event that Lilly appoints a third party to manufacture the
Product(s), Lilly shall be solely responsible and liable for the
performance of the manufacturer. Lilly shall ensure that said
manufacturer's facility is an FDA-approved facility and that such facility
complies with all relevant FDA and other relevant governmental and
regulatory requirements and that all then-current Good Manufacturing
Practices are adhered to. In no case will Lilly appoint a third party to
manufacture the Product(s) if that third party is a competitor with
Emisphere in the oral protein delivery field or if that third party is
involved in pending or threatened litigation with Emisphere.
16
Confidentiality Requested by
Emisphere Technologies, Inc.
SEC File No. 1-10615
6.4 Pursuant to the procedures set forth in the Manufacturing Responsibilities
Document, the quality and form of the Product(s) delivered by Lilly
hereunder shall conform in all material aspects to the Specifications and
all prevailing legislative and regulatory requirements of the countries
where the Product(s) are manufactured and to be used.
7. EXPLOITATION OF LICENSED TECHNOLOGY
7.1 Lilly will have the exclusive right to develop and/or exploit the Field.
In order to commercialize the Product(s), Lilly shall use commercially
reasonable efforts (consistent with its efforts on products of similar
commercial importance) to obtain marketing approval for and Launch the
Product(s) in such countries in the Territory as is determined by normal
Lilly business practices. It may be necessary to file an INDA or NDA and
perform clinical testing in more than one country. The conduct of such
clinical trials and the obtaining of regulatory approvals shall be
controlled and completed by Lilly.
7.2 The strategy for the registration and the commercialization of the
Product(s) shall be determined by Lilly. Upon inquiry, Emisphere shall be
advised as to Lilly's general commercialization strategy on a semi-annual
basis. For each country in which the Product is Launched, Lilly shall
inform Emisphere of the Launch at least [* * *] prior to the expected date
therefor.
7.3 Lilly shall exert its reasonable efforts to commercialize the Product(s)
in each country of the Territory where Lilly has Launched Product(s).
Such efforts shall be consistent with Lilly's efforts on products of
similar commercial importance.
7.4 Lilly will be solely responsible for ensuring that the manufacture,
promotion, distribution, marketing and sale of the Product(s) within each
country of the Territory is in strict accordance with all the legal and
regulatory requirements of each country of the Territory.
7.5 All advertising, promotional materials and marketing costs needed to
exploit the Product(s) are to be paid by Lilly. All package inserts, and
any advertising or promotional materials that substantially reproduce the
material included in the package inserts, shall, to the extent allowed by
applicable law or regulation, include: (i) acknowledgment that the Product
uses Emisphere technology; (ii) Emisphere's trade name (whether or not
registered); and (iii) Emisphere's logo (whether or not registered). Such
incorporation by Lilly shall be made upon discussion between Emisphere and
Lilly with respect to the appropriate protection of Emisphere's trademark,
service xxxx or trade name rights, and pursuant to a non-exclusive license
which Emisphere shall xxxxx Xxxxx for such purpose at the appropriate
time.
17
Confidentiality Requested by
Emisphere Technologies, Inc.
SEC File No. 1-10615
8. FINANCIAL PROVISIONS
8.1 In consideration of the research and development work conducted by
Emisphere for and on behalf of Lilly pursuant to the Research and
Development Program, Lilly shall pay Emisphere the sums agreed to by the
Parties pursuant to Clause 5.1, above, subject to the proper documentation
of research and development work and expenses.
8.2 In consideration of the granting of a license of the Emisphere Technology
to Xxxxx, Xxxxx shall make Milestone payments and pay royalties on Net
Sales of the Product(s) in the amounts and at the rates set forth in
Appendix 1 of the Option Agreement, as modified by the Activation Letter
attached hereto as Schedule II.
8.3 Lilly's obligation to pay royalties shall expire on a country-by-country
basis upon the conclusion of the term of this Agreement, as set forth in
Clause 12.1. Emisphere shall file for patent protection on Emisphere
Technology and Emisphere Program Technology included in the Product in
those countries listed in Exhibit C to the Option Agreement.
8.4 Payment of royalties shall be made quarterly within [* * *] after the
expiry of the calendar quarter; provided, that if the information
--------
necessary to make such payments is not available within such [* * *]
period, Lilly shall have an additional [* * *] to make such payments. The
method of payment shall be by wire transfer to an account specified by
Emisphere, or by such other manner as is mutually acceptable to the
Parties. Each payment made to Emisphere shall be accompanied by a written
report, prepared and signed by the appropriate royalty administration
personnel of Lilly. The report shall clearly show the Net Sales for the
calendar quarter for which payment is being made on a country-by-country
basis. In the event that no royalty is due to Emisphere for any quarterly
period, Lilly's appropriate royalty administration officer shall so
report.
8.5 Lilly shall maintain and keep clear, detailed, complete, accurate and
separate records so:
8.5.1 as to enable any royalties on Net Sales of the Product(s) which
shall have accrued hereunder to be determined; and
8.5.2 that any deductions made in arriving at the Net Sales can be
determined by Emisphere.
8.6 All payments due hereunder shall be made in United States Dollars.
Lilly's standard exchange rate methodology will be employed for the
translation of foreign currency sales into United States Dollars. This
methodology shall be
18
Confidentiality Requested by
Emisphere Technologies, Inc.
SEC File No. 1-10615
the one used by Lilly in the translation of its foreign currency operating
results for external reporting, shall be consistent with general accepted
accounting principles, and shall be the one approved and reviewed by
Lilly's independent certified public accountants.
8.7 Subject to the provisions of Clauses 8.8 and 8.10 of this Agreement, Lilly
shall pay all royalties at full rate.
8.8 If, at any time, legal restrictions in the Territory prevent the prompt
payment of running royalties or any portion thereof, the Parties shall
meet to discuss suitable and reasonable alternative methods of reimbursing
Emisphere the amount of such running royalties. In the event that Lilly is
prevented from making any payment under this Agreement by virtue of the
statutes, laws, codes or government regulations of the country from which
the payment is to be made, then such payments may be paid by depositing
them in the currency in which they accrue to an account set up for
Emisphere in a bank acceptable to Emisphere in the country the currency of
which is involved or as otherwise agreed by the Parties.
8.9 Emisphere and Lilly agree to co-operate in all respects necessary to take
advantage of any double taxation agreements or similar agreements as may,
from time to time, be available.
8.10 All taxes levied on payment of royalties accruing to Emisphere under this
Agreement shall be paid by Emisphere. If applicable laws or regulations
require withholding taxes by Lilly, the taxes will be deducted by Lilly
from remittable royalties and will be paid by Lilly on account of
Emisphere to the appropriate government tax authority.
9. RIGHT OF AUDIT AND INSPECTION
9.1 Within the term of this Agreement and within one year after its
termination, Emisphere shall not more than [* * *] each year have the
right at its expense to have Lilly's independent certified public
accountants inspect and audit Lilly's records for any of the two preceding
years for the purpose of determining the accuracy of royalty payments.
The independent certified accountants shall keep confidential any
information obtained during such inspection and shall report to Emisphere
only the amounts of Net Sales and royalties due and payable. Any such
inspection of Lilly's records shall be at the expense of Emisphere, except
that if any such inspection reveals a deficiency in the amount of the
running royalty actually paid to Emisphere hereunder in any calendar year
of [* * *]% or more of the amount of any running royalty actually due to
Emisphere hereunder, then the expense of such inspection shall be borne
solely by Lilly. Any amount of deficiency shall be paid promptly to
Emisphere. If such inspection reveals a surplus in the
19
Confidentiality Requested by
Emisphere Technologies, Inc.
SEC File No. 1-10615
amount of running royalty actually paid to Emisphere by Lilly, Emisphere
shall reimburse Lilly the surplus.
9.2 Within the term of this Agreement and within one year after its
termination, Lilly shall not more than [* * *] each year have the right at
its expense to have Emisphere's independent certified public accountants
inspect and audit Emisphere's records and accompanying reports (and all
associated documentation) for any of the two preceding years for the
purpose of determining the accuracy of Emisphere's reported, [* * *] and
Costs with respect to any Research and Development Program. The
independent certified public accountants shall keep confidential all
materials subject to third-party confidentiality agreements and all
materials not directly relevant to the purpose of their audit. Any such
inspection of Emisphere's records shall be at the expense of Lilly, except
that if any such inspection reveals an overpayment in the amount of such
Costs paid to Emisphere hereunder in any calendar year of [* * *] or more
of the amount of such Costs actually due to Emisphere hereunder, then the
expense of such inspection shall be borne solely by Emisphere instead of
by Lilly. Any surplus over the Costs properly payable by Lilly to
Emisphere shall be refunded promptly to Lilly. If such inspection reveals
a deficit in the amount of the Costs properly payable to Emisphere by
Xxxxx, Xxxxx shall pay the deficit to Emisphere.
9.3 In the event of any unresolved dispute regarding any alleged deficiency or
overpayment of royalty payments or Cost payments hereunder, the matter
will be referred to the independent firm of certified public accountants
of [* * *] for a resolution of such dispute. The decision of said firm of
certified public accountants shall be binding on the Parties.
10. PATENTS
10.1 Emisphere shall be obliged to disclose promptly to Lilly inventions made
by or on behalf of Emisphere in connection with the performance of the
Research and Development Programs, any patentable inventions and
discoveries within the Emisphere Know-How that relate to the Field, the
Emisphere Program Know-How and any patentable Improvements developed by or
on behalf of Emisphere (other than pursuant to the Research and
Development Program).
10.2 The Parties shall discuss in good faith all material issues relating to
filing, prosecution and maintenance of Emisphere Patents (insofar as the
Emisphere Patents are of relevance to the Field), the Emisphere Program
Patents, any patentable inventions and discoveries within the Emisphere
Know-How that relate to the Field, and any patentable Improvements
developed by or on behalf of Emisphere or to protect such inventions
and/or Improvements as trade secrets (other than pursuant to the Research
and Development Program). Subject to agreement to the contrary the
following provisions shall apply:
20
Confidentiality Requested by
Emisphere Technologies, Inc.
SEC File No. 1-10615
10.2.1 Emisphere at its expense shall make a good faith effort (a) to
secure the grant of any patent applications within the Emisphere
Patents and Emisphere Program Patents; (b) to file and prosecute
patent applications on patentable inventions and discoveries
within the Emisphere Know-How and patentable Improvements (or to
protect such inventions and/or Improvements as trade secrets)
developed by or on behalf of Emisphere (other than pursuant to
the Research and Development Program); (c) to defend all such
applications against third party oppositions; and (d) to
maintain in force any issued letters patent within the Emisphere
Patents and Emisphere Program Patents (including any letters
patent that may issue covering any Improvements). Emisphere
shall have the sole right in its reasonable business discretion
to control such filing, prosecution, defense and maintenance;
provided however, that Lilly shall have a reasonable right to be
provided with copies of all documents relating to such filing,
prosecution, defense, and maintenance in sufficient time to
review such documents and comment thereon, if desired by Lilly,
prior to filing. Should Emisphere decide for commercial or other
reasons to abandon in any country any patent or patent
application pertaining to the Emisphere Patents or the Emisphere
Program Patents for those Carriers that (i) are part of a
Product which is either undergoing or has gone through a Lilly
clinical development program or (ii) Emisphere, in good faith,
reasonably believes may be utilized as part of a Product for
clinical development by Lilly, it shall first obtain Lilly's
written consent, which consent shall not be unreasonably
withheld.
10.2.2 In the event that Emisphere informs Lilly that it does not
intend to file patent applications on patentable inventions and
discoveries within the Emisphere Know-How or Emisphere Program
Know-How that relate to those Carriers that have gone through a
Lilly clinical development program or patentable Improvements
developed thereon by or on behalf of Emisphere (other than
pursuant to the Research and Development Program) in one or more
countries in the Territory or fails to file such an application
within a reasonable period of time, but in no event less than
four (4) months after disclosure to Lilly pursuant to Clause
10.1, at Emisphere's election, Lilly shall have the right, but
not the obligation, at Lilly's sole expense to file and
prosecute such patent application(s) in the name of Lilly and
Emisphere, upon written request from Lilly, shall execute all
documents, forms and declarations and do all things as shall be
reasonably necessary to enable Lilly to exercise such right. In
the event that Emisphere so elects and Lilly files any such
application, such application shall [* * *].
10.3 Emisphere shall assist Lilly in good faith regarding all material issues
that arise from their joint work on the Research and Development Program
relating to
21
Confidentiality Requested by
Emisphere Technologies, Inc.
SEC File No. 1-10615
filing, prosecution and maintenance of Lilly Patents (insofar as the
Lilly Patents are of relevance to the Field), the Lilly Program Patents
and any patentable inventions and discoveries within the Lilly Know-How
that relate to the Field. Such assistance will be provided, however,
only upon Lilly's request. Subject to agreement to the contrary, the
following provisions shall apply:
10.3.1 Lilly shall be solely responsible for all facets of filing and
prosecuting patent applications and maintaining and defending
patents within the Lilly Patents and the Lilly Program Patents,
including all expenses pertaining thereto.
10.3.2 Any assistance from Emisphere requested by Lilly with respect to
its obligations as set forth in this Clause 10.3 shall be
provided at Lilly's expense. Emisphere will use its best
reasonable efforts to provide such assistance in the manner
requested by Lilly.
10.4 With respect to any Joint Patents, Emisphere will prepare and file
patent applications on behalf of both Parties and will diligently
prosecute same. Prior to the contemplated filing, Emisphere shall submit
a substantially completed draft of such patent applications to Lilly for
approval, which approval shall not be unreasonably withheld or delayed.
In the event of an imminent statutory bar to patenting, Emisphere shall
have the right to file a patent application, for the invention on which
a patent would be barred, without first receiving approval from Lilly,
in order to preserve the patent rights to such invention. Lilly and
Emisphere shall equally bear the cost of preparing, filing, prosecuting
and maintaining any patent applications and patents falling within this
Clause 10.4. Should Emisphere not wish to file, prosecute, maintain or
issue any patent application falling within this Clause 10.4, or
maintain a patent issuing from any such patent applications, in any
particular country, Emisphere will xxxxx Xxxxx any necessary authority
to file, prosecute, maintain or issue such patent application, or
maintain such a patent, in the name of Lilly. However, in such case,
such patent application or patent for such country shall be considered
to be a Lilly Program Patent. Likewise, should Lilly not wish to file,
prosecute, maintain or issue any patent application falling with this
Clause 10.4, or maintain a patent issuing from such patent applications,
in any particular country, Lilly will grant Emisphere any necessary
authority to file, prosecute, issue and maintain such patent
application, or maintain such a patent, in the name of Emisphere.
However, in such case, such patent application or patent for such
country shall be considered to be an Emisphere Program Patent.
10.5 Emisphere and Lilly shall promptly inform the other in writing of any
alleged infringement of any patents within the Emisphere Patents, the
Emisphere Program Patents or the Joint Patents or of any alleged
misappropriation of trade secrets within the Emisphere Know-
22
Confidentiality Requested by
Emisphere Technologies, Inc.
SEC File No. 1-10615
How, the Emisphere Program Know-How or the Joint Know-How, as such
infringement or misappropriation relates to the Field, by a third party
of which it becomes aware and provide the other with any available
evidence of such infringement or misappropriation.
10.5.1 (a) Emisphere shall have the primary right, but not the
obligation, to institute, prosecute and control any action or
proceeding with respect to any infringement of any of the
Emisphere Technology or the Emisphere Program Technology by
counsel of its own choice. Lilly shall cooperate with Emisphere
at Emisphere's request in the prosecution of such action or
proceeding. If Emisphere reasonably determines that Lilly is an
indispensable Party to the action, Lilly hereby consents to be
joined. In such event, Lilly shall have the right to be
represented in that action by counsel of its own choice and at
Lilly's expense.
(b) If Emisphere fails to bring an action or proceeding within a
period of [* * *] days after receiving written notice from Lilly
or otherwise having knowledge of infringement of the Emisphere
Technology or the Emisphere Program Technology in the Field,
Lilly shall have the right to bring and control any such action
by counsel of its own choice and expense. If Lilly reasonably
determines that Emisphere is an indispensable Party to the
action, Emisphere hereby consents to be joined. In such event,
Emisphere shall have the right to be represented in that action
by counsel of its own choice and at Emisphere expense.
(c) No settlement, consent judgment or other voluntary final
disposition of a suit under this Clause 10.5.1 may be entered
into without the joint consent of Lilly and Emisphere (which
consent shall not be withheld unreasonably or delayed by either
Party).
(d) If Emisphere brings an action hereunder, any damages or
other monetary awards recovered by Emisphere attributable to
sales of Product shall be applied first to defray the costs and
expenses incurred in the action. If any balance remains,
Emisphere shall pay Lilly [* * *]% of such balance.
(e) If Emisphere fails to bring an action hereunder and Lilly
brings action, any damages or other monetary awards recovered by
Lilly attributable to sales of Product shall be applied first to
defray the costs and expenses incurred in the action. If any
balance remains, Lilly shall pay Emisphere [* * *]% of such
balance.
(f) In the alternative, the Parties may agree to institute such
proceedings in their joint names and shall reach agreement as to
the
23
Confidentiality Requested by
Emisphere Technologies, Inc.
SEC File No. 1-10615
proportion in which they will share the proceeds of any such
proceedings, and the expense of any costs not recovered.
(g) If the infringement of the Emisphere Patents or the
Emisphere Program Patents affects the Field as well as other
products being developed or commercialized by Emisphere or its
commercial partners, the Parties shall agree as to the manner in
which the proceedings should be instituted and shall reach
agreement as to the proportion in which they will share the
proceeds of any such proceedings, and the expense of any costs
not recovered.
10.5.2 During the term of this Agreement, Lilly shall have the first
right but not the obligation to bring suit or otherwise take
action against any alleged infringement of the Lilly Program
Patents or alleged misappropriation of the Lilly Program
Know-How. In the event that Lilly takes such action, Lilly shall
do so solely at its own cost and expense and all damages and
monetary award recovered in or with respect to such action shall
be the property of Lilly. At Lilly's reasonable request,
Emisphere will co-operate with any such action at Lilly's sole
cost and expense.
10.5.3 During the term of this Agreement, both Parties shall have the
right but not the obligation to bring suit or otherwise take
action against any alleged infringement of the Joint Patents or
alleged misappropriation of the Joint Know-How. Both Parties
shall be obligated to inform the other of any infringement or
misappropriation of which they become aware. The Parties shall
jointly determine in good faith how to manage any action with
respect to any such infringement or misappropriation. In the
alternative, or if one party desires to take such an action and
the other does not, the Party that takes such action shall do so
solely at its own cost and expense and all damages and monetary
award recovered in or with respect to such action shall be the
property of that Party. At such Party's reasonable request, the
other Party will co-operate with any such action at the
requesting Party's sole cost and expense.
10.6 Emisphere may defend against any Third Party claim that is related to
the Emisphere Patents, Emisphere Program Patents, Emisphere Know-How or
Emisphere Program Know-How. Lilly shall cooperate with Emisphere as may
be reasonably requested by Emisphere in such defense and shall have the
right to be represented by counsel of its own choice at Lilly's expense
provided that Emisphere shall (i) keep Lilly fully informed with regard
to the defense of such Third Party claim and (ii) obtain Lilly's prior
written approval before entering into any settlement in connection with
such Third Party claims, such approval not to be unreasonably withheld
or delayed.
24
Confidentiality Requested by
Emisphere Technologies, Inc.
SEC File No. 1-10615
If within [* * *] of receiving notice of any Third Party claim related
to the Field, Emisphere fails to defend against such Third Party claim,
Lilly may, at its own cost, defend against such Third Party claim;
provided that Lilly shall (i) keep Emisphere fully informed with regard
to the defense of such Third Party claim, and (ii) obtain Emisphere's
prior written approval before entering into any settlement in connection
with such Third Party claim, such approval not be unreasonably withheld
or delayed. Emisphere shall cooperate with Lilly as may reasonably be
requested by Lilly in such defense and shall have the right to be
represented by counsel of its own choice at Emisphere's expense. If
royalties or lump sum payments are due to the Third Party by reason of a
court order or litigation settlement, such payment shall be solely the
responsibility of Lilly, provided that [* * *]% of such Third Party
royalties or lump sum payments shall be offset against royalties payable
to Emisphere under this Agreement, not to exceed the royalties due
Emisphere, as also set forth in Clause 13.1.
10.7 Except as provided in Clauses 10.6 and 13.1, Emisphere shall have no
liability to Lilly whatsoever or howsoever arising for any losses
incurred by Lilly as a result of having to cease selling Product(s) or
having to defer the Launch of Product(s) as a result of any infringement
proceedings.
11. CONFIDENTIAL INFORMATION
11.1 The Parties acknowledge that it may be necessary, from time to time, to
disclose to each other confidential and proprietary information,
including without limitation, inventions, works of authorship, trade
secrets, specifications, designs, data, know-how and other information,
relating to the Field, the Compounds, the Carriers, the Products,
processes, and services of the disclosing Party or regarding the
Emisphere Technology or Emisphere Program Technology or the Lilly
Technology or the Lilly Program Technology. The foregoing shall be
referred to collectively as "Confidential Information". Any Confidential
Information revealed by a Party to another Party shall be used by the
receiving Party exclusively for the purposes of fulfilling the receiving
Party's obligations under this Agreement.
11.2 Each Party agrees to disclose Confidential Information of another Party
only to those employees, representatives and agents requiring knowledge
thereof in connection with their duties directly related to the
fulfilling of the Party's obligations under this Agreement. Each Party
agrees that it will exercise the same degree of care, but in no event
less than a reasonable degree, and protection to preserve the
proprietary and confidential nature of the Confidential Information
disclosed by the other Party, as the receiving Party would exercise to
preserve its own proprietary and confidential information. Each Party
agrees that it will, upon request of the other Party, return all
documents and any copies thereof containing Confidential Information
25
Confidentiality Requested by
Emisphere Technologies, Inc.
SEC File No. 1-10615
belonging to or disclosed by, such Party if such documents are not
required to perform its obligations hereunder, and further provided that
the returning party may keep one copy of all such documents in its legal
archive for recording purposes.
11.3 With respect to all Confidential Information furnished by one Party to
the other pursuant to this Agreement, either in writing or orally, the
Party receiving such Confidential Information shall maintain the
confidential and proprietary status of such Confidential Information,
keep such Confidential Information and each part thereof within its
possession or under its control, use all its reasonable efforts to
prevent the disclosure of any Confidential Information to any other
person, and use all its reasonable efforts to ensure that such
Confidential Information is used only for those purposes specifically
authorized by this Agreement. These mutual obligations of
confidentiality shall apply until ten (10) years after termination or
expiration of this Agreement. Confidential Information, further, shall
not be deemed to include any information to the extent that such
information is:
(a) independently developed by the recipient as documented by prior
written records outside the scope and not in violation of this
Agreement;
(b) in the public domain at the time of its receipt or thereafter
becomes part of the public domain through no fault of the recipient;
(c) received without an obligation of confidentiality from a third party
having the right to disclose such information;
(d) released from the restrictions of this Clause 11 by the express
written consent of the disclosing Party;
(e) required by law, statute, rule or court order to be disclosed (the
disclosing Party shall, however, use reasonable efforts to obtain
confidential treatment of any such disclosure, consult with the other
Party and permit the other Party to participate in seeking an
appropriate protective order).
Notwithstanding the provisions of this Clause 11, Emisphere and Lilly
may, to the extent necessary, disclose and use Confidential Information
only for the purpose of carrying out their duties and obligations under
this Agreement (i) to any Affiliate, sublicensee or subcontractor of
either Emisphere or Lilly hereunder (if such sublicensee or
subcontractor is subject to provisions substantially similar to those
set forth in this Clause 11); (ii) to secure patent protection, pursuant
to Clause 10 hereof, for an invention developed as a result of the
collaboration undertaken pursuant to this Agreement or (iii) to obtain
institutional or government approval to test clinically or market any
Product subject to confidential treatment if possible.
26
Confidentiality Requested by
Emisphere Technologies, Inc.
SEC File No. 1-10615
11.4 The Parties agree that the obligations of this Clause 11 are necessary
and reasonable in order to protect the Parties' respective businesses,
and each Party expressly agrees that monetary damages would be
inadequate to compensate a Party for any breach by the other Party of
its covenants and agreements set forth herein. Accordingly, the Parties
agree and acknowledge that any such violation or threatened violation
will cause irreparable injury to a Party and that, in addition to any
other remedies that may be available, in law and equity or otherwise,
any Party shall be entitled to obtain injunctive relief against the
threatened breach of the provisions of this Clause 11, or a continuation
of any such breach by the other Party, specific performance and other
equitable relief to redress such breach together with its damages and
reasonable counsel fees and expenses to enforce its rights hereunder,
without the necessity of proving actual or express damages.
12. TERM OF AGREEMENT
12.1 Subject to the provisions for earlier termination set out in Clauses
12.2, 12.3, and 12.6 and the provisions regarding the payment of
royalties in Clause 8, the term of this Agreement shall be a period
commencing as of the Effective Date and expiring on a country by country
basis on the last to occur of:
12.1.1 nine (9) years from the date of Launch of the Product(s) in the
country concerned; or
12.1.2 upon the expiration of the last to expire patent included in the
Emisphere Patents, the Emisphere Program Patents and/or the
Joint Patents to the extent that any such patents cover
Products(s).
12.2 In addition to the rights of early or premature termination provided for
elsewhere in this Agreement, in the event that any of the terms or
provisions hereof are incurably breached by either Party, the non-
breaching Party may immediately terminate this Agreement by written
notice. Subject to the other provisions of this Agreement, in the event
of any other breach, the non-breaching Party may terminate this
Agreement by giving written notice to the breaching Party that this
Agreement will terminate on the sixtieth (60th) day from notice unless
cure is sooner effected. If the breaching Party has proposed a course of
action to rectify the breach and is acting in good faith to rectify same
but has not cured the breach by the sixtieth (60th) day, the said period
shall be extended by such period as is reasonably necessary to enable
the breach to be cured. If termination of this Agreement pursuant to
this Clause 12.2 is caused by a breach of this Agreement by Xxxxx, Xxxxx
shall lose all rights pursuant to Clauses 2 and 3 above. If Emisphere
breaches this Agreement then restitution to Lilly appropriate for the
degree of the breach shall be made, and Lilly shall continue payments
pursuant to a mutually acceptable escrow agreement until the matter is
resolved.
27
Confidentiality Requested by
Emisphere Technologies, Inc.
SEC File No. 1-10615
12.3 As used in this Clause 12, the term "Event of Bankruptcy" relating to
either Party shall mean:
(a) the appointment of a liquidator, receiver, administrator, examiner,
trustee or similar officer over either Party or over all or a
substantial part of its assets under the law of any applicable
jurisdiction, including without limit, the United States of America;
or
(b) an application or petition for bankruptcy, corporate re-
organization, composition, administration, examination, arrangement
or any other procedure similar to any of the foregoing under the law
of any applicable jurisdiction, including without limitation, the
United States of America, is filed, and is not discharged within
thirty (30) days, or if either Party applies for or consents to the
appointment of a receiver, administrator, examiner or similar
officer over it or over all or a material part of its assets, rights
or revenues or the assets and/or the business of either Party are
for any reason seized, confiscated or condemned.
12.3.1 If at any time during the term of this Agreement, an "Event of
Bankruptcy" (as defined above) relating to Emisphere occurs, Lilly
shall have, in addition to all other legal and equitable rights and
remedies available hereunder, the option to terminate this Agreement
upon thirty (30) days' written notice, given within sixty (60) days
following the date that Lilly becomes aware of the Event of
Bankruptcy. Upon such termination by Xxxxx, Xxxxx shall be entitled
to solely continue the activities conducted or to be conducted
pursuant to this Agreement but for the Event of Bankruptcy.
12.3.2 If at any time during the term of this Agreement, an "Event of
Bankruptcy" (as defined above) relating to Lilly occurs, other than
in circumstances where the Event of Bankruptcy arises directly or
indirectly as a result of a dispute with Emisphere and it is
unlikely that the Event of Bankruptcy would have arisen if Lilly and
Emisphere had been in agreement, rather than in dispute, Emisphere
shall have, in addition to all other legal and equitable rights and
remedies available hereunder, the option to terminate this Agreement
upon thirty (30) days' written notice, given within sixty (60) days
following the date that Emisphere becomes aware of the Event of
Bankruptcy.
12.4 Upon exercise of those rights of termination as specified in Clause 12.1
to Clause 12.3 inclusive or elsewhere within the Agreement, this Agreement
shall, subject to the other provisions of the Agreement, automatically
terminate forthwith and be of no further legal force or effect.
28
Confidentiality Requested by
Emisphere Technologies, Inc.
SEC File No. 1-10615
12.5 Upon expiration or termination of the Agreement:
12.5.1 any sums that were due from Lilly to Emisphere on Net Sales in
the Territory or in such particular country or countries in the
Territory, as the case may be, prior to the expiration or
termination of this agreement as set forth herein shall be paid
in full within [* * *] ([* * *] if the information necessary to
make such payment is not available within such [* * *] period)
of the expiration or termination of this Agreement for the
Territory or for such particular country or countries in the
Territory, as the case may be;
12.5.2 all confidentiality provisions set out herein shall remain in
full force and effect;
12.5.3 all responsibilities and warranties shall insofar as are
appropriate remain in full force and effect;
12.5.4 the rights of inspection and audit set out in Clause 9 shall
continue in force for a period of one year;
12.5.5 except as expressly provided for under Clauses 12.2 and 12.5.7
all rights and licenses granted in and pursuant to this
Agreement shall cease for the Territory or for such particular
country or countries in the Territory, as the case may be.
Following such expiration or termination, Lilly may not
thereafter, except as expressly provided for in Clauses 12.2 and
12.5.7, use in the Territory or in such particular country or
countries in the Territory, as the case may be, (a) any valid
and unexpired Emisphere Patents or Emisphere Program Patents
and/or (b) any Emisphere Know-How or Emisphere Program Know-How
that remains confidential or otherwise proprietary to Emisphere;
and
12.5.6 to the extent this Agreement is terminated (as opposed to
expired) in the Territory or any particular country in the
Territory, Lilly shall promptly make an accounting to Emisphere
of the inventory of the Product(s) which it has in the Territory
or for such particular country or countries in the Territory, as
the case may be, if any, as of the date of such termination and
Lilly shall have the right for a period of [* * *] after said
termination to sell such inventory of the Product(s) in the
Territory or in such particular country or countries in the
Territory, as the case may be, or, if appropriate and legally
permissible, to transport such inventory of Product(s) for sale
in another country or countries in the Territory within such [*
* *] period; provided that the Net Sales thereof shall be
subject to the royalty provisions of Clause 8 and so payable to
Emisphere. Thereafter, any remaining inventory of
29
Confidentiality Requested by
Emisphere Technologies, Inc.
SEC File No. 1-10615
Product(s) shall be disposed of by mutual agreement of the
Parties in accordance with regulatory requirements.
12.5.7 upon the conclusion of the term of this Agreement in any
particular country, Lilly shall have a fully paid-up, exclusive
license to make or use the Emisphere Know-How and Emisphere
Program Know-How for the Products in the Field in that country.
Upon such conclusion of the term of this Agreement in any
particular country, [* * *].
12.6 Lilly shall have the option to terminate the Agreement upon [* * *]
prior written notice to Emisphere. Lilly shall pay for any and all
external (to Lilly) research and development commitments by Emisphere in
place at the time of such notice of termination to the extent that
Emisphere cannot terminate the same without penalty.
If Lilly terminates this Agreement without cause (e.g., for reasons
other than safety of the Carriers, clinical results of the Product, or
the Emisphere Technology efficiency), the Parties will issue a joint
press release which states that the termination was not due to the
Emisphere Technology, and that Lilly will continue to evaluate the
Emisphere Technology with respect to other Lilly therapeutic Compounds.
13. WARRANTIES/INDEMNITIES
13.1 Emisphere represents and warrants that it has the sole, exclusive and
unencumbered right to grant the licenses and rights herein granted to
Lilly, and that it has not granted any option, license, right or
interest in or to the Emisphere Technology, the Emisphere Program
Technology, the Carriers or the Product(s) to any third party which
would conflict with the rights granted by this Agreement.
In the case where the Emisphere Technology or the Emisphere Program
Technology is covered by a patent or patents (or other intellectual
property rights) held by an Independent Third Party, and both Emisphere
and Lilly agree that a license is required under any such patent (or
other intellectual property right) for the Parties to utilize the
Emisphere Technology or the Emisphere Program Technology, Emisphere
shall obtain such license and shall not pass on to Lilly, in any manner,
any of the costs associated with obtaining such a license, including
royalties to the Independent Third Party. In no case, however, shall
Emisphere be required to obtain such a license if the costs of so doing
would exceed the royalty payments by Lilly provided for hereunder.
However, Lilly shall be permitted to obtain such a license and deduct
from royalties otherwise due to Emisphere the costs of obtaining the
license, up to a limit of all royalty payments due to Emisphere
hereunder. In any such case,
30
Confidentiality Requested by
Emisphere Technologies, Inc.
SEC File No. 1-10615
Lilly, in its negotiations with the Independent Third Party with respect
to the amount of compensation for such a license, shall act in good
faith vis a vis Emisphere.
13.2 Lilly represents and warrants that it has the sole, exclusive and
unencumbered right to grant the licenses and rights herein granted to
Emisphere and that it has not granted any option, license, right or
interest in or to the Lilly Technology or the Lilly Program Technology
to any third party which would conflict with the rights granted by this
Agreement.
In the case where the Lilly Technology or the Lilly Program Technology
is covered by a patent or patents (or other intellectual property
rights) held by an Independent Third Party, and, as a result thereof,
either (i) Lilly is prohibited from continuing the development or sale
of a Product or (ii) Lilly ceases development or sale of a Product
because the costs associated with obtaining the rights to proceed with
development or sale of the Product make such continued development or
sale uneconomic in Lilly's sole judgment, then the licenses granted
hereunder by Emisphere shall no longer be exclusive to Lilly, and
Emisphere shall, in its sole discretion, have the right to enter into a
license agreement with such Independent Third Party for use of the
Emisphere Technology or Emisphere Program Technology in the development
or sale of the Product. The foregoing shall not be interpreted so as to
imply any license of the Lilly Technology or the Lilly Program
Technology to Emisphere or to the Independent Third Party, nor shall
this clause be deemed an impediment to any agreement among Emisphere,
Lilly and the Independent Third Party to develop or sell the Product.
13.3 Emisphere represents and warrants that to the best of its knowledge, the
true inventors of the subject matter claimed are named in the Emisphere
Patents and all such inventors have irrevocably assigned all their
rights and interests therein to Emisphere.
13.4 Emisphere represents and warrants that it is not aware of any
information material to the examination of the Emisphere Patents that
was not disclosed to the United States Patent Office.
13.5 Emisphere and Lilly represent and warrant for the benefit of each other
that the execution of this Agreement by them and the full performance
and enjoyment of the rights of them under this Agreement will not breach
the terms and conditions of any license, contract, understanding or
agreement, whether express, implied, written or oral between them and
any third party.
13.6 Emisphere and Lilly represent and warrant for the benefit of each other
that as of the Effective Date of executing this Agreement, to the best
of their knowledge no patents, trade secrets or any other proprietary
rights of any
31
Confidentiality Requested by
Emisphere Technologies, Inc.
SEC File No. 1-10615
third party would be infringed by the manufacture, use or sale of the
Product(s).
13.7 Lilly represents and warrants that with respect to all regulatory
filings to obtain NDA approvals, to the best of Lilly's knowledge, the
data and information in Lilly's submission(s) are and shall be free from
fraud or material falsity, that the NDA approvals have not been and will
not be obtained either through bribery or the payment of illegal
gratuities, that the data and information in Lilly's submissions are and
shall be accurate and reliable for purposes of supporting approval of
the submissions, and that the NDA approvals are and shall be obtained
without illegal or unethical behavior of any kind.
13.8 Lilly represents and warrants that the Product(s) sold by Lilly under
this Agreement shall conform to the Specifications and be in accordance
with all regulations and requirements of the FDA including the then
current Good Manufacturing Practice regulations which apply to the
manufacture and supply of the Product(s). Lilly represents and warrants
that the Product(s) sold by it shall not be adulterated or mis-branded
as defined by the US Federal Food, Drug and Cosmetic Act, and shall not
be a product which would violate any section of such Act if introduced
in interstate commerce. EXCEPT AS EXPRESSLY STATED IN THIS CLAUSE 13.8,
ALL OTHER WARRANTIES, CONDITIONS AND REPRESENTATIONS, EXPRESS OR
IMPLIED, STATUTORY OR OTHERWISE, INCLUDING A WARRANTY AS TO THE QUALITY
OR FITNESS FOR ANY PARTICULAR PURPOSE OF THE PRODUCT(S) ARE HEREBY
EXCLUDED AND LILLY SHALL NOT BE LIABLE IN CONTRACT, TORT OR OTHERWISE
FOR ANY LOSS, DAMAGE, EXPENSE OR INJURY OF ANY KIND WHATSOEVER,
CONSEQUENTIAL OR OTHERWISE, ARISING OUT OF OR IN CONNECTION WITH THE
PRODUCT(S) OR ANY DEFECT IN THE PRODUCT(S) OR FROM ANY OTHER CAUSE.
13.9 Lilly is fully cognizant of all applicable statutes, ordinances and
regulations of the Territory with respect to the manufacture of the
Product(s) including, but not limited to, the U.S. Federal Food, Drug
and Cosmetic Act and regulations thereunder, current Good Laboratory
Practices and current Good Manufacturing Practices. Lilly shall
manufacture the Product(s) in conformance with the Specifications and
the Drug Master File (which Lilly shall own), to the extent any such
Drug Master File exists, and in a manner which fully complies with such
statutes, ordinances, regulations and practices.
13.10 Emisphere represents and warrants that the Carrier supplied by Emisphere
under this Agreement shall conform to the Specifications and be in
accordance with all regulations and requirements of the FDA including
the then current Good Manufacturing Practice regulations which apply to
the manufacture and supply of the Carrier. Emisphere represents and
warrants that the Carrier supplied by it shall not be adulterated or
mis-branded as defined by the US
32
Confidentiality Requested by
Emisphere Technologies, Inc.
SEC File No. 1-10615
Federal Food, Drug and Cosmetic Act, and shall not be a product which
would violate any section of such Act if introduced in interstate
commerce. EXCEPT AS EXPRESSLY STATED IN THIS CLAUSE 13.10, ALL OTHER
WARRANTIES, CONDITIONS AND REPRESENTATIONS, EXPRESS OR IMPLIED,
STATUTORY OR OTHERWISE, INCLUDING A WARRANTY AS TO THE QUALITY OR
FITNESS FOR ANY PARTICULAR PURPOSE OF THE PRODUCT(S) ARE HEREBY EXCLUDED
AND EMISPHERE SHALL NOT BE LIABLE IN CONTRACT, TORT OR OTHERWISE FOR ANY
LOSS, DAMAGE, EXPENSE OR INJURY OF ANY KIND WHATSOEVER, CONSEQUENTIAL OR
OTHERWISE, ARISING OUT OF OR IN CONNECTION WITH THE PRODUCT(S) OR ANY
DEFECT IN THE PRODUCT(S) OR FROM ANY OTHER CAUSE.
13.11 Emisphere is fully cognizant of all applicable statutes, ordinances and
regulations of the Territory with respect to the manufacture of the
Carrier including, but not limited to, the U.S. Federal Food, Drug and
Cosmetic Act and regulations thereunder, current Good Laboratory
Practices and current Good Manufacturing Practices. Emisphere shall
manufacture the Carrier in conformance with the Specifications and the
Drug Master File and in a manner which fully complies with such
statutes, ordinances, regulations and practices. Emisphere shall own the
Drug Master File with respect to the Carriers, and Lilly shall have
access and a right of review thereto with respect to its manufacture of
Carriers and its regulatory filings.
13.12 In addition to any other indemnifications provided for herein, Emisphere
shall indemnify and hold harmless Lilly and its Affiliates and their
respective employees, agents, partners, officers and directors from and
against any claims, losses, liabilities or damages (including reasonable
attorney's fees and expenses) incurred or sustained by Lilly arising out
of or in connection with any (a) breach of any representation, covenant,
warranty or obligation by Emisphere hereunder, or (b) any act or
omission on the part of Emisphere or any of its agents or employees in
the performance of this Agreement.
13.13 In addition to any other indemnifications provided for herein, Lilly
shall indemnify and hold harmless Emisphere and its Affiliates and their
respective employees, agents, partners, officers and directors from and
against any claims, losses, liabilities or damages (including reasonable
attorney's fees and expenses) incurred or sustained by Emisphere arising
out of or in connection with any (a) breach of any representation,
covenant, warranty or obligation by Lilly hereunder, or (b) any act or
omission on the part of Lilly or any of its agents or employees in the
performance of this Agreement.
13.14 Lilly shall assume the sole and entire responsibility and shall
indemnify and hold harmless Emisphere from any and all claims,
liabilities, expenses, including reasonable attorney's fees,
responsibilities and damages by reason of any claim, proceedings,
action, liability or injury arising out of any faults of
33
Confidentiality Requested by
Emisphere Technologies, Inc.
SEC File No. 1-10615
the Product(s) resulting from the transport, packaging, storage,
handling, distribution, marketing or sale of the Product(s) by Lilly, to
the extent that it was caused by the negligence or wrongful acts or
omissions on the part of Lilly.
13.15 Emisphere shall assume the sole and entire responsibility and shall
indemnify and hold harmless Lilly from any and all claims, liabilities,
expenses, including reasonable attorney's fees, responsibilities and
damages by reason of any claim, proceeding, action, liability or injury
arising out of any faults of the Carrier(s) resulting from the
transport, packaging, storage, handling, distribution, marketing or sale
of the Carrier(s) by Emisphere, to the extent that it was caused by the
negligence or wrongful acts or omissions on the part of Emisphere.
13.16 As a condition of obtaining an indemnity in the circumstances set out
above, the Party seeking an indemnity shall:
13.16.1 fully and promptly notify the other Party of any claim or
proceeding, or threatened claim or proceeding;
13.16.2 permit the indemnifying Party to take full care and control of
such claim or proceeding;
13.16.3 cooperate in the investigation and defense of such claim or
proceeding;
13.16.4 not compromise or otherwise settle any such claim or proceeding
without the prior written consent of the other Party, which
consent shall not be unreasonably withheld, conditioned or
delayed; and
13.16.5 take all reasonable steps to mitigate any loss or liability in
respect of any such claim or proceeding.
13.7 NOTWITHSTANDING ANYTHING TO THE CONTRARY IN THIS AGREEMENT, EMISPHERE
AND LILLY SHALL NOT BE LIABLE TO THE OTHER BY REASON OF ANY
REPRESENTATION OR WARRANTY, CONDITION OR OTHER TERM OR ANY DUTY OF
COMMON LAW, OR UNDER THE EXPRESS TERMS OF THIS AGREEMENT, FOR ANY
CONSEQUENTIAL OR INCIDENTAL LOSS OR DAMAGE (WHETHER FOR LOSS OF PROFIT
OR OTHERWISE) AND WHETHER OCCASIONED BY THE NEGLIGENCE OF THE RESPECTIVE
PARTIES, THEIR EMPLOYEES OR AGENTS OR OTHERWISE WHETHER OR NOT THEY HAVE
BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
34
Confidentiality Requested by
Emisphere Technologies, Inc.
SEC File No. 1-10615
14. REGULATORY APPROVALS
14.1 Any and all INDAs, NDAs and other applications for regulatory approval
filed hereunder for the Product(s) shall be the responsibility and
property of Lilly. Lilly shall allow Emisphere access thereto to enable
Emisphere to fulfill its obligations and exercise its rights under this
Agreement. Lilly will be responsible for all regulatory filings in all
countries and shall allow Emisphere access to related correspondence, to
the extent such access is necessary to enable Emisphere to fulfill its
obligations and exercise its rights under this Agreement. In particular,
Lilly agrees to inform Emisphere should any such correspondence
reasonably pertain to the Emisphere Technology or the Emisphere Program
Technology. The Parties shall collaborate in relation to obtaining the
approval of the FDA for final approved labeling.
14.2 Save as otherwise outlined in this Agreement, the costs and expenses of
any filings and proceedings made by Lilly to the FDA, including post
approval studies required by the FDA in respect of the Product(s), and
to maintain the FDA approval hereunder shall be paid by Lilly.
14.3 Lilly shall indemnify and hold harmless Emisphere, its agents and
employees from and against all claims, damages, losses, liabilities and
expenses to which Emisphere, its agents, and employees may become
subject related to or arising out of Lilly's bad faith, gross negligence
or intentional misconduct in connection with the filing or maintenance
or failure to file or maintain or prosecute the NDA.
14.4 Subject to the provisions of Clause 14.4, it is hereby acknowledged that
there are inherent uncertainties involved in the registration of
pharmaceutical products with the FDA insofar as obtaining approval is
concerned and such uncertainties form part of the business risk involved
in undertaking the form of commercial collaboration as set forth in this
Agreement. Therefore, save for using its reasonable efforts, Lilly and
Emisphere shall have no liability to each other solely as a result of
any failure of the Product(s) to achieve the approval of the FDA, or any
other regulatory body in the Territory.
14.5 Should the Parties receive a notice of regulatory inspection from any
governmental agency, or if the Parties receive notice of any potential
regulatory action, relative to the Carrier, the Parties will have an
obligation to notify each other of same.
Emisphere will prepare and provide Lilly with all information deemed
necessary by Lilly for worldwide regulatory submission of the Product
(Lilly will provide Emisphere with a template for such submissions,
which Emisphere shall prepare and provide the relevant information to
Lilly). Emisphere shall also provide Lilly with necessary access to any
regulatory filings worldwide
35
Confidentiality Requested by
Emisphere Technologies, Inc.
SEC File No. 1-10615
relevant to the Product and Lilly shall be entitled to use the
information contained therein in its own regulatory filings on the
Product. Should Emisphere wish, at any time during the term of this
Agreement, to modify its regulatory filings relating to the Product,
Emisphere shall provide Lilly with written notification of its
intentions prior to making such modification. Any proposed modification
not required by law, government or regulatory agency must be responded
to by Lilly within thirty (30) days. If Lilly's response is not received
by Emisphere within 30 days, approval of such proposal shall be deemed
to have been granted. Finally, to the extent details of the regulatory
filing process are not set forth in this section or elsewhere in the
Agreement, the Steering Committee shall decide any such matters.
15. INSURANCE
15.1 Lilly shall maintain comprehensive general liability insurance,
including product liability insurance on the Product(s) manufactured
and/or sold in such prudent amount as shall be determined by Lilly
management for the duration of this Agreement and for a period of two
(2) years thereafter.
15.2 Emisphere shall maintain comprehensive general liability insurance,
including product liability insurance on the Carrier(s) manufactured for
and/or sold to Lilly in such prudent amount as shall be determined by
Emisphere management for the duration of this Agreement and for a period
of two (2) years thereafter. Emisphere shall also provide Lilly with a
vendor's certificate for the Carriers substantially in a form to be
agreed between the Parties.
16. IMPOSSIBILITY OF PERFORMANCE - FORCE MAJEURE
16.1 Neither Party to this Agreement shall be liable for delay in the
performance of any of its obligations hereunder if such delay results
from causes beyond its reasonable control, including, without
limitation, acts of God, fires, strikes, acts of war, or intervention of
a government authority, non availability of raw materials, but any such
delay or failure shall be remedied by such Party as soon as practicable.
17. SETTLEMENT OF DISPUTES; PROPER LAW
17.1 The Parties will attempt in good faith to resolve any dispute arising
out of or relating to this Agreement promptly by negotiation between the
Chief Executive Officer of Emisphere and (a) the Vice President of
Science, Technology and Proteins if the dispute is prior to Launch of
Products in any country in the Territory, or (b) if the dispute arises
after such Launch, then the Vice President of Lilly's general business
unit responsible for the Product at issue. In the event that such
negotiations do not result in a mutually acceptable resolution, the
Parties agree to consider other dispute resolution
36
Confidentiality Requested by
Emisphere Technologies, Inc.
SEC File No. 1-10615
mechanisms including mediation. Subject to the provisions of Clause
17.2, in the event that the Parties fail to agree on a mutually
acceptable dispute resolution mechanism, any such dispute shall be
finally settled by a court of competent jurisdiction. The Parties hereby
submit to the jurisdiction of the state and Federal courts located in
the state of New York.
17.2 This Agreement shall be governed by and construed in accordance with the
laws of New York without reference to conflicts of laws principles.
18. ASSIGNMENT
18.1 This Agreement may not be assigned by either Party without the prior
written consent of the other, which consent shall not be unreasonably
withheld, conditioned or delayed, save that either Party may assign this
Agreement to its Affiliate or to any successor by merger or sale of
substantially all of the assets of its business unit to which this
Agreement relates without such consent, provided that such assignment
does not have any adverse tax consequences on the other Party. Emisphere
and Lilly will discuss any assignment by either Party to an Affiliate
prior to its implementation in order to avoid or reduce any additional
tax liability to the other Party resulting solely from different tax law
provisions applying after such assignment to an Affiliate. For the
purpose hereof, an additional tax liability shall be deemed to have
occurred if either Party would be subject to a higher net tax on
payments made hereunder after taking into account any applicable tax
treaty and available tax credits than such Party was subject to before
the proposed assignment.
19. NOTICES
19.1 Any notice to be given under this Agreement shall be sent in writing in
English by registered mail or telefaxed to the following addresses:
If to Lilly:
Xxx Xxxxx and Company
Lilly Xxxxxxxxx Xxxxxx
Xxxxxxxxxxxx, XX 00000
Attention: General Patent Counsel
Telephone: (000) 000-0000
Telefax: (000) 000-0000
37
Confidentiality Requested by
Emisphere Technologies, Inc.
SEC File No. 1-10615
If to Emisphere:
Emisphere Technologies, Inc.
00 Xxxxxxx Xxxxx
Xxxxxxxxx, XX 00000
Attention: Vice President Business Development
Telephone: (000) 000-0000
Telefax: (000) 000-0000
or to such other address(es) and telefax number(s) as may from time to
time be notified by either Party to the other hereunder.
19.2 Any notice sent by mail shall be deemed to have been delivered within
[* * *] working days after dispatch and any notice sent by telefax shall
be deemed to have been delivered within [* * *] the time of the
dispatch. Notice of change of address shall be effective upon receipt.
20. MISCELLANEOUS CLAUSES
20.1 No waiver of any right under this Agreement shall be deemed effective
unless contained in a written document signed by the Party charged with
such waiver, and no waiver of any breach or failure to perform shall be
deemed to be a waiver of any other breach or failure to perform or of
any other right arising under this Agreement.
20.2 If any provision in this Agreement is agreed by the Parties to be, or is
deemed to be, or becomes invalid, illegal, void or unenforceable under
any law that is applicable hereto, (i) such provision will be deemed
amended to conform to applicable laws so as to be valid and enforceable
or, if it cannot be so amended without materially altering the intention
of the Parties, it will be deleted, with effect from the date of such
agreement or such earlier date as the Parties may agree, and (ii) the
validity, legality and enforceability of the remaining provisions of
this Agreement shall not be impaired or affected in any way.
20.3 The Parties shall use their respective reasonable endeavors to ensure
that the Parties and any necessary third party shall do, execute and
perform all such further deeds, documents, assurances, acts and things
as any of the Parties hereto may reasonably require by notice in writing
to the other Party or such third party to carry the provisions of this
Agreement.
20.4 This Agreement shall be binding upon and inure to the benefit of the
Parties hereto, their successors and permitted assigns and
sub-licensees.
38
Confidentiality Requested by
Emisphere Technologies, Inc.
SEC File No. 1-10615
20.5 No provision of this Agreement shall be construed so as to negate,
modify or affect in any way the provisions of any other agreement
between the Parties unless specifically referred to, and solely to the
extent provided, in any such other agreement. In the event of a conflict
between the provisions of this Agreement and the provisions of the
Option Agreement, the terms of the Option Agreement shall prevail unless
this Agreement specifically provides otherwise.
20.6 No amendment, modification or addition hereto shall be effective or
binding on either Party unless set forth in writing and executed by a
duly authorized representative of each Party.
20.7 This Agreement may be executed in any number of counterparts, each of
which when so executed shall be deemed to be an original and all of
which when taken together shall constitute this Agreement.
20.8 Each of the Parties undertakes to do all things reasonably within its
power which are necessary or desirable to give effect to the spirit and
intent of this Agreement.
20.9 Each of the Parties hereby acknowledges that in entering into this
Agreement it has not relied on any representation or warranty save as
expressly set out herein or in any document referred to herein.
20.10 Nothing contained in this Agreement is intended or is to be construed to
constitute Emisphere and Lilly as partners, or Emisphere as an employee
of Lilly, or Lilly as an employee of Emisphere. Neither Party hereto
shall have any express or implied right or authority to assume or create
any obligations on behalf of or in the name of the other Party or to
bind the other Party to any contract, agreement or undertaking with any
third party.
20.11 This Agreement has been jointly prepared and shall not be strictly
construed against any Party.
20.12 The parties hereto agree to disclose publicly through a joint press
release, upon signing this Agreement, the nature and scope of the
Agreement. All press releases, scientific papers and all other public
disclosures related to this Agreement shall be approved in advance by
both parties, except for such disclosures permitted pursuant to Clause
11, above, such approval not to be unreasonably withheld or delayed.
Upon the occurrence of other significant events in the Research and
Development Program or other activities hereunder, Emisphere and Lilly
agree to make joint press releases. In all cases Lilly shall have the
right to review portions of any SEC filings by Emisphere that relate
directly to Lilly; in no case shall either party release information
which would allow a third party to determine the actual Carriers
(including,
39
Confidentiality Requested by
Emisphere Technologies, Inc.
SEC File No. 1-10615
without limitation, the Carrier/Compound complex in the Product)
developed hereunder.
IN WITNESS THEREOF the Parties hereto have executed this Agreement in
duplicate.
SIGNED BY
For and on behalf of
Xxx Xxxxx and Company
in the presence of:
SIGNED BY Xxxxxxx X. Xxxxxxxx, M.D.
For and on behalf of
Emisphere Technologies, Inc.
in the presence of:
40
Confidentiality Requested by
Emisphere Technologies, Inc.
XXX Xxxx Xx. 0-00000
XXXXXXXX I
[* * *] Content Check List
[* * *]
1
